Navigation Links
Herceptin Again Proves Mettle Against Breast Cancer
Date:1/28/2010

Improved survival seen when used with chemo for HER2 malignancies, researchers report

THURSDAY, Jan. 28 (HealthDay News) -- High-risk breast cancer patients with HER2-positive tumors benefit from receiving the targeted therapy Herceptin while undergoing chemotherapy, new research shows.

"It's in a European journal [The Lancet], but it's something many of us in the U.S. have already begun to do," said Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge, La. "It just confirms what has really become standard of care in this country, but it's very nice to see it done in a scientific way," he added.

"The reason why Herceptin is so valuable to patients who have locally advanced breast cancer is they have a very bad prognosis," he continued. "The cancers are usually bigger. They may have spread to the lymph nodes in the armpits and they're usually not small enough to be cut out to preserve the breast."

When Brooks sees a patient with locally advanced breast cancer, he treats them first with chemotherapy, to shrink the tumor, along with trastuzumab (Herceptin). Once chemo is completed -- after about six months -- it's easier to operate and remove the tumor. Then the patient is continued on Herceptin for a year, followed by radiation.

The new study, one of the largest looking at Herceptin in this context, was funded by Hoffmann-La Roche, which makes the drug. It appears in the Jan. 30 issue of The Lancet.

Previous research has shown that Herceptin with chemotherapy helped women with both early and metastatic breast cancer live longer.

According to the study authors, from IRCCS Istituto Nazionale de Tumori in Milan, about 22 percent of early breast cancers, 35 percent of locally advanced breast cancers and metastatic tumors, and 40 percent of inflammatory breast cancers overexpress HER2 (human epidermal growth factor receptor-2). These tumors tend to be more aggressive, resulting in shorter survival times.

For this study, 235 women were randomly assigned to receive chemotherapy either with or without one year of Herceptin. In this arm of the trial, the Herceptin was given with chemotherapy (before surgery), then alone.

The second group of patients received chemotherapy before surgery, but no Herceptin.

All participants had either HER2-positive locally advanced breast cancer or inflammatory breast cancer, a rare and deadly form of the disease.

Seventy-one percent of women who received Herceptin were alive without a recurrence at the end of three years, versus 56 percent of women in the control group.

Encouragingly, there were few cardiac problems in the Herceptin group and those that did experience heart problems responded to drugs. Previous studies had shown a much higher rate of heart problems in patients receiving Herceptin.

More information

For more on breast cancer, visit the U.S. National Cancer Institute.



SOURCES: Jay Brooks, M.D., chairman, hematology/oncology, Ochsner Health System, Baton Rouge, La.; Jan. 30, 2010, The Lancet


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Herceptin helps women with multiple chromosomes containing HER2 gene, study finds
2. Xeloda(R), Taxotere(R) and Herceptin(R) Combination Study Suggests Clinical Benefit in Invasive Breast Cancer with Shortened Treatment Cycle
3. If Herceptin is Approved in Combination With Other Emerging Therapies it Will be in a Position to Retain Patient Share From Tykerb/Tyverb for the Treatment of HER2-Positive Breast Cancer
4. Mathematical modeling predicts response to Herceptin
5. Routine Testing Would Improve Herceptin Use in Breast Cancer
6. Biosimilars of Rituxan, MabThera, Herceptin and Erbitux will Erode $8.2 Billion in U.S. and European Sales in 2018
7. Chemo With Herceptin May Be Best for Some Breast Cancers
8. Mayo Clinic researchers say breast cancer survival improves Herceptin used with chemotherapy
9. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
10. Antioxidants show no clear benefit against cardiovascular events, death in high-risk women
11. Despite overeating, morbidly obese mice gain protection against diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... U.S. Surgeon General, Dr. Vivek Murthy, ... Murthy explains how he was inspired to practice medicine at an early age by ... about more than making diagnoses and prescribing medicine,” he states. “It is about building ...
(Date:12/2/2016)... York, NY (PRWEB) , ... December 02, 2016 , ... ... high school and while 84 percent of parents report speaking with their child about ... pornography and sexually transmitted diseases. , Mediaplanet is proud to announce the launch of ...
(Date:12/2/2016)... ... December 02, 2016 , ... Universal Medical Systems, ... and the first company to offer robotic imaging to veterinary medicine is sponsoring ... # 941 for the American Association of Equine Practitioners 62nd Annual Convention from ...
(Date:12/2/2016)... ... December 02, 2016 , ... "Pro3rd Accents Volume 2 is a ... versatile lower third titles with just a few clicks of the mouse," said Christina ... 30 lower third animations. Choose from various styles with accented animations, rigid boxes, simplistic ...
(Date:12/2/2016)... ... December 02, 2016 , ... Date aired: ... of Type 2 Diabetes: The Owner’s Manual, http://realtimepressrelease.com/press-releases-tagged-with/daryl-wein , Sharon ... of Water, Global Climate Change and Your Health radio program syndicated on Voice ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... bioLytical Laboratories, ein Weltführer bei schnellen Tests für Infektionskrankheiten, hat sein ... eingeführt. Continue Reading ... ... , ... ) bioLytical wurde durch die Clinton Health Access ...
(Date:12/2/2016)... Dec. 2, 2016 Boston Scientific Corporation (NYSE: ... to acquire certain manufacturing assets and capabilities of the ... advanced biological tissue business, as well as a 15% ... million in cash. The Neovasc advanced biological tissue business ... Boston Scientific Lotus™ Valve System. * Upon completion ...
(Date:12/2/2016)... Lianluo Smart Limited (Nasdaq: ... develops, markets and sells medical devices and wearable ... and international markets, recently attended the 2016 ... Progress Forum, co-hosted by the Institute of Interventional ... Guangdong Provincial People,s Hospital and Cardiology Department of ...
Breaking Medicine Technology: